Annual report pursuant to Section 13 and 15(d)

Segment Information (Details)

v3.20.1
Segment Information (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Segment Reporting Information [Line Items]    
Number of Reportable Segments | segment 1  
Net Revenue $ 36,629 $ 26,882
Direct cost of goods (10,532) (6,125)
Sales and marketing costs (17,120) (11,639)
Research and development (81,326) (87,383)
General and administrative (38,470) (41,732)
Other Expenses 9,159 (10,803)
Segment gain (loss) from operations (110,819) (119,997)
Intangible asset, net 7,377 1,417
Tangible assets 219,045 139,576
Segment assets 226,422 140,993
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Segment gain (loss) from operations $ (101,660) (130,800)
Segment assets   140,993
Dermatology Products Sales [Member]    
Segment Reporting Information [Line Items]    
Number of Reportable Segments | segment 2  
Dermatology Products Sales [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Net Revenue $ 34,921 23,376
Direct cost of goods (10,532) (6,125)
Sales and marketing costs (17,120) (11,639)
Research and development 0 0
General and administrative (2,556) (1,778)
Other Expenses 0  
Segment gain (loss) from operations 4,713 3,834
Intangible asset, net 7,377 1,417
Tangible assets 19,946 8,984
Segment assets 27,323 10,401
Pharmaceutical and Biotechnology Product Development [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Net Revenue 1,708 3,506
Direct cost of goods 0  
Sales and marketing costs 0 0
Research and development (81,326) (87,383)
General and administrative (35,914) (39,954)
Other Expenses 9,159 (10,803)
Segment gain (loss) from operations (106,373) (134,634)
Intangible asset, net 0  
Tangible assets 199,099 130,592
Segment assets $ 199,099 $ 130,592
National Holdings Corporation [Member]    
Segment Reporting Information [Line Items]    
Number of Reportable Segments | segment 3